Find a Trial
Trial Results
5 protocol(s) meet the specified criteria
CTO-A011801OPEN TO ACCRUAL
THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB
CTO-CTMX-2009-002OPEN TO ACCRUAL
A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity
of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of
CX-2009 as Monotherapy and in Combination with CX-072 in Advanced
Triple-Negative Breast Cancer (CTMX-2009-002)
CTO-EA1181OPEN TO ACCRUAL
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
Part 1 Component of:
The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
CTO-M19-345OPEN TO ACCRUAL
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors
S1609OPEN TO ACCRUAL
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS